Limits...
Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice.

Park HR, Ju EJ, Jo SK, Jung U, Kim SH, Yee ST - BMC Cancer (2009)

Bottom Line: Although cisplatin is one of the most effective chemotherapeutic agents, cisplatin alone does not achieve a satisfactory therapeutic outcome.HemoHIM itself did not inhibit melanoma cell growth in vitro, and did not disturb the effects of cisplatin in vitro.Also, HemoHIM reduced nephrotoxicity as seen by tubular cell of kidney destruction.

View Article: PubMed Central - HTML - PubMed

Affiliation: Radiation Resarch Division for Bio-Technology, Advanced Radiation Technology Institute, Jeongeup Campus of Korea Atomic Energy Research Institute (KAERI), 1266 Sinjeong-dong Jeongeup-si Jeonbuk 580-185, Republic of Korea. hrpark@kaeri.re.kr

ABSTRACT

Background: Although cisplatin is one of the most effective chemotherapeutic agents, cisplatin alone does not achieve a satisfactory therapeutic outcome. Also cisplatin accumulation shows toxicity to normal tissues. In this study, we examined the possibility of HemoHIM both to enhance anticancer effect with cisplatin and to reduce the side effects of cisplatin in melanoma-bearing mice.

Methods: HemoHIM was prepared by adding the ethanol-insoluble fraction to the total water extract of a mixture of 3 edible herbs, Angelica Radix, Cnidium Rhizoma and Paeonia Radix. Anticancer effects of HemoHIM with cisplatin were evaluated in melanoma-bearing mice. We used a Cr51-release assay to measure the activity of NK/Tc cell and ELISA to evaluate the production of cytokines.

Results: In melanoma-bearing mice, cisplatin (4 mg/kg B.W.) reduced the size and weight of the solid tumors, and HemoHIM supplementation with cisplatin enhanced the decrease of both the tumor size (p < 0.1) and weight (p < 0.1). HemoHIM itself did not inhibit melanoma cell growth in vitro, and did not disturb the effects of cisplatin in vitro. However HemoHIM administration enhanced both NK cell and Tc cell activity in mice. Interestingly, HemoHIM increased the proportion of NK cells in the spleen. In melanoma-bearing mice treated with cisplatin, HemoHIM administration also increased the activity of NK cells and Tc cells and the IL-2 and IFN-gamma secretion from splenocytes, which seemed to contribute to the enhanced efficacy of cisplatin by HemoHIM. Also, HemoHIM reduced nephrotoxicity as seen by tubular cell of kidney destruction.

Conclusion: HemoHIM may be a beneficial supplement during cisplatin chemotherapy for enhancing the anti-tumor efficacy and reducing the toxicity of cisplatin.

Show MeSH

Related in: MedlinePlus

Growth inhibition effect of cisplatin and HemoHIM on melanoma cells in vitro. The melanoma cells were seeded at a density of 7 × 103 cells per well. After incubation for 24 hours, cells were treated with various concentration of cisplatin and with HemoHIM 100 μg/ml for 24 hours. After incubation, a CCK-8 solution was added to each well for 1 hour and then the optical density was measured.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2666758&req=5

Figure 3: Growth inhibition effect of cisplatin and HemoHIM on melanoma cells in vitro. The melanoma cells were seeded at a density of 7 × 103 cells per well. After incubation for 24 hours, cells were treated with various concentration of cisplatin and with HemoHIM 100 μg/ml for 24 hours. After incubation, a CCK-8 solution was added to each well for 1 hour and then the optical density was measured.

Mentions: The anticancer effect of cisplatin mainly depends on its DNA-damaging activity, via its direct interaction with DNA to form DNA adducts [27]. As shown in Fig. 3, cisplatin inhibited melanoma cell growth in a dose-dependent manner, with IC50 at about 15 μg/ml. However, HemoHIM itself did not inhibit melanoma growth in vitro (Data not shown), nor did it disturb the working of cisplatin in vitro (Fig. 3).


Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice.

Park HR, Ju EJ, Jo SK, Jung U, Kim SH, Yee ST - BMC Cancer (2009)

Growth inhibition effect of cisplatin and HemoHIM on melanoma cells in vitro. The melanoma cells were seeded at a density of 7 × 103 cells per well. After incubation for 24 hours, cells were treated with various concentration of cisplatin and with HemoHIM 100 μg/ml for 24 hours. After incubation, a CCK-8 solution was added to each well for 1 hour and then the optical density was measured.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2666758&req=5

Figure 3: Growth inhibition effect of cisplatin and HemoHIM on melanoma cells in vitro. The melanoma cells were seeded at a density of 7 × 103 cells per well. After incubation for 24 hours, cells were treated with various concentration of cisplatin and with HemoHIM 100 μg/ml for 24 hours. After incubation, a CCK-8 solution was added to each well for 1 hour and then the optical density was measured.
Mentions: The anticancer effect of cisplatin mainly depends on its DNA-damaging activity, via its direct interaction with DNA to form DNA adducts [27]. As shown in Fig. 3, cisplatin inhibited melanoma cell growth in a dose-dependent manner, with IC50 at about 15 μg/ml. However, HemoHIM itself did not inhibit melanoma growth in vitro (Data not shown), nor did it disturb the working of cisplatin in vitro (Fig. 3).

Bottom Line: Although cisplatin is one of the most effective chemotherapeutic agents, cisplatin alone does not achieve a satisfactory therapeutic outcome.HemoHIM itself did not inhibit melanoma cell growth in vitro, and did not disturb the effects of cisplatin in vitro.Also, HemoHIM reduced nephrotoxicity as seen by tubular cell of kidney destruction.

View Article: PubMed Central - HTML - PubMed

Affiliation: Radiation Resarch Division for Bio-Technology, Advanced Radiation Technology Institute, Jeongeup Campus of Korea Atomic Energy Research Institute (KAERI), 1266 Sinjeong-dong Jeongeup-si Jeonbuk 580-185, Republic of Korea. hrpark@kaeri.re.kr

ABSTRACT

Background: Although cisplatin is one of the most effective chemotherapeutic agents, cisplatin alone does not achieve a satisfactory therapeutic outcome. Also cisplatin accumulation shows toxicity to normal tissues. In this study, we examined the possibility of HemoHIM both to enhance anticancer effect with cisplatin and to reduce the side effects of cisplatin in melanoma-bearing mice.

Methods: HemoHIM was prepared by adding the ethanol-insoluble fraction to the total water extract of a mixture of 3 edible herbs, Angelica Radix, Cnidium Rhizoma and Paeonia Radix. Anticancer effects of HemoHIM with cisplatin were evaluated in melanoma-bearing mice. We used a Cr51-release assay to measure the activity of NK/Tc cell and ELISA to evaluate the production of cytokines.

Results: In melanoma-bearing mice, cisplatin (4 mg/kg B.W.) reduced the size and weight of the solid tumors, and HemoHIM supplementation with cisplatin enhanced the decrease of both the tumor size (p < 0.1) and weight (p < 0.1). HemoHIM itself did not inhibit melanoma cell growth in vitro, and did not disturb the effects of cisplatin in vitro. However HemoHIM administration enhanced both NK cell and Tc cell activity in mice. Interestingly, HemoHIM increased the proportion of NK cells in the spleen. In melanoma-bearing mice treated with cisplatin, HemoHIM administration also increased the activity of NK cells and Tc cells and the IL-2 and IFN-gamma secretion from splenocytes, which seemed to contribute to the enhanced efficacy of cisplatin by HemoHIM. Also, HemoHIM reduced nephrotoxicity as seen by tubular cell of kidney destruction.

Conclusion: HemoHIM may be a beneficial supplement during cisplatin chemotherapy for enhancing the anti-tumor efficacy and reducing the toxicity of cisplatin.

Show MeSH
Related in: MedlinePlus